Cerebellar allografts survive and transiently alleviate ataxia in a transgenic model of spinocerebellar ataxia type-1.
Spinocerebellar ataxia type 1 (SCA-1) is one of several neurodegenerative diseases, including Huntington's disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy, and SCA-2, SCA-3, SCA-6, and SCA-7, each caused by an expanded number of CAG repeats in the coding region of their respective genes. The mechanism by which the resulting proteins are pathogenic is unknown. Clinical trials of neural transplants in Huntington's disease patients are under way. While initial reports are encouraging, definitive evidence of graft survival in patients despite the ongoing disease process is not possible with current imaging techniques. Transplants in primates have shown long-term survival of striatal grafts and recovery of function, but have used lesioning to model Huntington's phenotypically. Studies of striatal grafts in a transgenic mouse model of Huntington's have not yet shown a behavioral benefit. We describe a behavioral benefit of cerebellar grafts in a transgenic model of SCA-1 in which the ataxic phenotype results from expression of an expanded ataxin-1 protein. Mice were transplanted at an age when their ataxic phenotype is just becoming evident. Compared with sham-operated littermates, grafted mice showed better performance on multiple behavioral tests of cerebellar function. Differences persisted for 10 to 12 weeks posttransplant, after which there was a progressive decline in motor performance. At 20 weeks postsurgery, donor Purkinje cell survival was evident in 9 of 12 graft recipients. These results indicate that transplants can have behavioral benefits and grafts can survive long-term despite the ongoing pathological process in a brain actively expressing an expanded polyglutamine protein.
Department of Laboratory Medicine and Pathology, Department of Neurosurgery, University of Minnesota, 2001 Sixth Street S.E., Minneapolis, Minnesota, 55455, USA.
W F
WF
Kaemmerer
W C
WC
Low
D000818:Animals; D000067696:Ataxin-1; D000067528:Ataxins; D016380:Brain Tissue Transplantation / Q000473:pathology / Q000502:physiology*; D002531:Cerebellum / Q000166:cytology / Q000502:physiology* / Q000637:transplantation*; D003433:Crosses, Genetic; D003712:Dendrites / Q000648:ultrastructure; D016332:Fetal Tissue Transplantation / Q000473:pathology / Q000502:physiology*; D005684:Gait / Q000502:physiology; D006085:Graft Survival; D006579:Heterozygote; D006801:Humans; D006816:Huntington Disease / Q000235:genetics / Q000601:surgery*; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D009043:Motor Activity / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics*; D011689:Purkinje Cells / Q000166:cytology / Q000473:pathology; D013132:Spinocerebellar Degenerations / Q000235:genetics / Q000503:physiopathology / Q000601:surgery*; D014184:Transplantation, Homologous; D018911:Trinucleotide Repeats
C000593749:ATXN1 protein, human; D000067696:Ataxin-1; D000067528:Ataxins; C000593750:Atxn1 protein, mouse; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins